Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD34+ Cells for Myocardial Ischemia and Heart Failure
NCT00346177Phase 2
Key facts
- Status
- Withdrawn
- Start
- Sep 2010
- Primary completion
- Sep 2011
- Countries
- 1
- Modality
- Stem Cell Therapies
- Conditions
- Myocardial ischemia (MI)heart failure (HF)
01
Overview
Phase 2, randomised, double-blind trial of autologous CD34+ cells in Myocardial ischemia (MI) and heart failure (HF). Planned start Sep 2010; status: withdrawn.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms.
Beyond the preview
Go deeper on NCT00346177.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346177.